Oral Versus Intravenous Dexamethasone in Community-acquired pneumonia study

Phase 4

Completed

• Conditions: lower respiratory tract infection; Pneumonia; 10024970

• Registration Number: NL-OMON36192
• Lead Sponsor: Sint Antonius Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

- Aged 18 years and older
- Presenting to the emergency room with suspected pneumonia (to be confirmed within 24 hours from admission)
- Pneumonia is defined as a new or progressive infiltrate on a chest X-ray plus at least two of the following criteria: cough, sputum production, temperature >38°C or <35°C, ausculatory findings consistent with pneumonia, leucocytosis or leucopenia (>10 g/l, <4 g/l or >10% rods in leucocyte differentiation), C-reactive protein >3 times the upper normal limit
- Corticosteroid naive at time of presentation

Exclusion Criteria

- Patients needing corticosteroid treatment above study medication
- Failure to obtain written consent to participate
- Patients using fenytoine, barbiturates, rifampicine, erythromycin, clarithromycine, aprepitant, colchicine, everolimus, itraconazol, ketoconazole, pazopamib, tipranavir, vinorelbin
- Moribund patients (defined as expected to die within 24 hours)
- Patients with proven or suspected allergy to dexamethasone
- Patient not capable of taking tablets orally

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Extent of exposure reflected by the area under concentration time curve<br /><br>(AUC0-24)</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Cmax, Tmax and Ctrough</p><br>